AroCell

The study evaluated serum samples from 208 men diagnosed with castrate resistant prostate cancer at the Medical University of Vienna and Semmelweis University, Budapest. Results show that patients with elevated serum levels of both sTK1 and TPS responded significantly better to docetaxel-based chemotherapy compared to androgen receptor pathway inhibitors (ARPIs) such as enzalutamide or abiraterone.

Key Findings:

• Patients with high sTK1 and TPS levels had a median overall survival of 14.6 months when treated with docetaxel, compared to only 6.8 months with ARPIs.
• Patients with low biomarker levels showed no significant difference in survival between treatment types, suggesting that ARPIs remain a viable option in these cases.
• The predictive value of the biomarkers aligns with established mechanisms of drug action where docetaxel is known to target rapidly dividing cells.

 
“Prostate cancer is the most common cause of cancer-related death among men in Sweden. This study shows that a blood test based on a combination of serum TK1 and TPS may help clinicians to choose the most optimal treatment for men with advanced stages of this disease.” Professor Stig Linder.